Bernard Lerer: Pre-clinical, translational and clinical research focused on the use of psychedelic drugs and their derivatives to treat psychiatric disorders
Psychedelics January 25, 2024 DOI: 10.61373/pp024k.0004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Key points | The text is a biographical sketch of Professor Bernard Lerer, highlighting his directorship of the Center for Psychedelic Research and his prior 30-year tenure as Head of the Biological Psychiatry Unit. It notes the center's research focus on psychedelic drugs for psychiatric disorders but presents no empirical findings or arguments. |
Abstract
Professor Bernard Lerer is in the Faculty of Medicine, Hebrew University, Jerusalem, Israel, where he is Director the Center for Psychedelic Research (https://cfpr.brainlabs.org.il/) at Hadassah Medical Center, in Jerusalem. The Center has a growing staff that includes senior scientists, post-docs, Ph.D. and graduate students, technicians, and psychiatrists undergoing research training. Their research is preclinical, translational, and clinical and focuses on the use of psychedelic drugs and their derivatives to treat psychiatric disorders. Previously, he was Head of the Biological Psychiatry Unit at Hadassah Medical Center for 30 years, with research and clinical responsibilities. A conversation with Professor Lerer covered topics on his life and career.